Skip to main content
Josep M. Llovet

Josep M. Llovet

Institut d'Investigacions Biomèdiques August Pi i Sunyer

Life & Medical Sciences

Josep M Llovet, MD, PhD is ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine – Hepatic Oncology at the University of Barcelona. Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York). He has published 329 manuscripts in Liver Cancer (citations:85552; h-index:117; IF:6077). Top 1% most cited researcher globally by Clarivate Analytics (2014-21). Major achievement: a) Defining molecular and immune classes of hepatocellular carcinoma (HCC), particularly NASH-HCC, and cholangiocarcinoma (CCA), b) discovery of drivers as therapeutic targets  HCC and FGFR2 fusion (CCA) and c) Establishing Standard therapies for HCC, such as sorafenib, regorafenib and ramucirumab. He has been Senior Editor CCR, President of ILCA (2011-13), lectured > 605 international meetings and PI of competitive grants FP7 & Horizon-HEPTROMIC, HEP-CAR, Accelerator Award and NIH R01-award.

Research interests

Prof Josep M. Llovet research has been focused on clinical and translational studies in liver cancer for the last 26 years. He is leading international randomized trials on novel targeted therapies and developing a molecular and immune classification of the disease, understanding the genetic aberrations and signaling pathways involved and in the identification of new molecular targeted therapies. He has organized the HCC Genomic Consortium that includes international research centers: IDIBAPS-Hospital Clínic, Icahn School of Medicine at Mount Sinai, INSERM, Univ. Tuebingen, Dana-Farber-MIT-Broad Institute and NCI. The main areas of interest are a) identify biomarkers predicting response and resistance to checkpoint inhibitors and combination therapies for hepatocellular carcinoma (HCC) b) translate oncogenic drivers discoveries as targeted therapies in liver cancer, c) unraveling the molecular traits of NASH-HCC onset, progression and response to immunotherapies.

Selected publications

– Pinyol, R, Torrecilla S, Wang, H….Llovet, JM. 2021. ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’, Journal Of Hepatology 75:865 – 878.

– Torrens L, Montironi C; Puigvehi M… Llovet JM. 2021. ‘Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma’. Hepatology. 74:2652-2669.

– Haber  PK, Puigvehi M, Castet F,…Llovet, JM. 2021, ‘Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)’, Gastroenterology, 161:879 – 898.

– Pfister D, Nunez NG, Pinyol R, …Llovet JM, Heikenwalder M. 2021. NASH limits anti-tumor surveillance in immunotherapy-treated HCC. Nature. 592:450-456

Llovet, JM, De Baere, T, Kulik L, Haber, PK, Greten, TF, Meyer T, Lencioni, R. 2021, ‘Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma’, Nature Reviews Gastroenterology & Hepatology, 18:293-313.

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. 2021. Hepatocellular Carcinoma. Nat Rev Dis Primers. 7:6

ICREA Memoir 2021